Evidence map›Paper›PMID 31591533›Full record

ReviewNature reviews. Immunology2020

Precursor exhausted T cells: key to successful immunotherapy?

Axel Kallies, Dietmar Zehn, Daniel T Utzschneider

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 313 papers.

0numbers the graph read from it
0cells of the map it votes in
313citing papers in PubMed
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

313 citing papers in PubMed, 459 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Targeting T follicular helper cells for lifelong health.Nature reviews. Drug discovery · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

253 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Axel KalliesDepartment of Microbiology & Immunology Melbourne, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia. axel.kallies@unimelb.edu.au.ORCID http://orcid.org/0000-0002-6312-6968
Dietmar ZehnDivision of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.ORCID http://orcid.org/0000-0003-1393-8527
Daniel T UtzschneiderDepartment of Microbiology & Immunology Melbourne, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia. daniel.utzschneider@unimelb.edu.au.
The University of Melbourne · AUTechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytotoxic T cell immunity in response to chronic infections and tumours is maintained by a specialized population of CD8

Indexed as

Antineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesCell DifferentiationHumansImmunologic MemoryNeoplasmsPrecursor Cells, T-LymphoidProgrammed Cell Death 1 ReceptorT-Lymphocyte SubsetsAntineoplastic Agents, ImmunologicalProgrammed Cell Death 1 Receptor

Identifiers

PMID31591533
OpenAlexW2978325001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.